These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. In-vitro antiviral efficacy of ribavirin and interferon-alpha against canine distemper virus. Carvalho OV; Saraiva GL; Ferreira CG; Felix DM; Fietto JL; Bressan GC; Almeida MR; Silva Júnior A Can J Vet Res; 2014 Oct; 78(4):283-9. PubMed ID: 25355997 [TBL] [Abstract][Full Text] [Related]
25. Drug repurposing of quinine as antiviral against dengue virus infection. Malakar S; Sreelatha L; Dechtawewat T; Noisakran S; Yenchitsomanus PT; Chu JJH; Limjindaporn T Virus Res; 2018 Aug; 255():171-178. PubMed ID: 30055216 [TBL] [Abstract][Full Text] [Related]
26. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817 [TBL] [Abstract][Full Text] [Related]
27. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection. Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956 [TBL] [Abstract][Full Text] [Related]
28. Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines. Franco EJ; Tao X; Hanrahan KC; Zhou J; Bulitta JB; Brown AN Microorganisms; 2021 Feb; 9(2):. PubMed ID: 33540830 [TBL] [Abstract][Full Text] [Related]
29. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin. Larrey D; Carenco C; Guyader D; Boyer N; Benhamou Y; Pageaux GP; Rouzier R; Marcellin P Antivir Ther; 2012; 17(5):927-32. PubMed ID: 22611092 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of dengue antiviral candidates in vivo in mouse model. Watanabe S; Vasudevan SG Methods Mol Biol; 2014; 1138():391-400. PubMed ID: 24696350 [TBL] [Abstract][Full Text] [Related]
33. Live Cell Analysis and Mathematical Modeling Identify Determinants of Attenuation of Dengue Virus 2'-O-Methylation Mutant. Schmid B; Rinas M; Ruggieri A; Acosta EG; Bartenschlager M; Reuter A; Fischl W; Harder N; Bergeest JP; Flossdorf M; Rohr K; Höfer T; Bartenschlager R PLoS Pathog; 2015 Dec; 11(12):e1005345. PubMed ID: 26720415 [TBL] [Abstract][Full Text] [Related]
34. Identification of the phytobioactive Polygonum cuspidatum as an antiviral source for restricting dengue virus entry. Kuo YT; Liu CH; Li JW; Lin CJ; Jassey A; Wu HN; Perng GC; Yen MH; Lin LT Sci Rep; 2020 Oct; 10(1):16378. PubMed ID: 33009425 [TBL] [Abstract][Full Text] [Related]
35. A novel flavivirus entry inhibitor, BP34610, discovered through high-throughput screening with dengue reporter viruses. Yang CC; Hu HS; Lin HM; Wu PS; Wu RH; Tian JN; Wu SH; Tsou LK; Song JS; Chen HW; Chern JH; Chen CT; Yueh A Antiviral Res; 2019 Dec; 172():104636. PubMed ID: 31654671 [TBL] [Abstract][Full Text] [Related]
36. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients. Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582 [TBL] [Abstract][Full Text] [Related]
37. Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes. Shiffman ML; Verbeke SB; Kimball PM Antiviral Res; 2000 Nov; 48(2):91-9. PubMed ID: 11114411 [TBL] [Abstract][Full Text] [Related]
38. [Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C]. Pawłowska M; Palewicz E; Halota W Przegl Epidemiol; 2006; 60(1):71-7. PubMed ID: 16758742 [TBL] [Abstract][Full Text] [Related]
39. Characterization of the activity of 2'-C-methylcytidine against dengue virus replication. Lee JC; Tseng CK; Wu YH; Kaushik-Basu N; Lin CK; Chen WC; Wu HN Antiviral Res; 2015 Apr; 116():1-9. PubMed ID: 25614455 [TBL] [Abstract][Full Text] [Related]
40. Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys. Farias KJ; Machado PR; Muniz JA; Imbeloni AA; da Fonseca BA Viral Immunol; 2015 Apr; 28(3):161-9. PubMed ID: 25664975 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]